Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
NCT05577728
Completed
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist
NCT06500429
Completed
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg BID) or placebo for 5 days beginning on Day 1. On Day 2, all participants will receive a single subcutaneous injection of a GLP-1 agonist (semaglutide). Participants will remain at the clinical research unit for the duration of the treatment period. The goal of this clinical trial is to evaluate the safety and efficacy of NG101 compared to placebo, when also administered along with a... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/23/2024
Locations: Celerion, Tempe, Arizona
Conditions: Overweight and Obesity, Healthy
Register for Updates
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
NCT05478252
Completed
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months)... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/16/2024
Locations: Velocity Clinical Research San Diego, La Mesa, California +64 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
NCT04216589
Completed
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Alabama CRS (Site ID: 31788), Birmingham, Alabama +8 locations
Conditions: HIV Infections, Non-Alcoholic Fatty Liver Disease
Register for Updates
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
NCT05227196
Completed
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks. The study will last up to 29 to 31 weeks for each participant. This includes a screenin... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/06/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California +2 locations
Conditions: Healthy Volunteers, Type 2 Diabetes
Register for Updates
A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
NCT05784402
Completed
In this study, a known investigational medicine called 'semaglutide' will be tested in 2 different tablet versions. In addition to semaglutide, the tablet versions contain different helping agents in different amounts. Both tablet versions have a helping agent called SNAC. The main aim of this study is to investigate semaglutide of 4 different doses in a new tablet by determining the amount of semaglutide in the blood and compare the concentration in the blood for the new tablet with the tablet... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/06/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California +1 locations
Conditions: Healthy Participants
Register for Updates
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
NCT04969939
Completed
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: Diablo Clinical Research, Inc., Walnut Creek, California +13 locations
Conditions: Obesity
Register for Updates
Semaglutide Use in Elderly Obese Patients
NCT05302596
Active Not Recruiting
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/27/2024
Locations: Diabetes and Endocrinology Research Center, Buffalo, New York
Conditions: Obesity, Aging
Register for Updates
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
NCT06282458
Active Not Recruiting
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Gender:
ALL
Ages:
Between 60 years and 100 years
Trial Updated:
08/08/2024
Locations: Pinnacle Trials, Anniston, Alabama +13 locations
Conditions: Muscle Loss, Obesity
Register for Updates
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
Completed
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/06/2024
Locations: Central Alabama Research, Birmingham, Alabama +832 locations
Conditions: Overweight, Obesity
Register for Updates
Mechanisms of Semaglutide Therapy in Heart Failure Patients
NCT06541509
Recruiting
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which remain poorly defined. In large clinical trials, semaglutide improved the outcomes in obese patients, patie... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
08/05/2024
Locations: Greenstone Biosciences, Palo Alto, California +2 locations
Conditions: Heart Failure, Obesity
Register for Updates
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
NCT05819853
Recruiting
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.
Gender:
FEMALE
Ages:
Between 12 years and 35 years
Trial Updated:
07/29/2024
Locations: University of Colorado Anschutz/Children's Hospital Colorado Aurora, Aurora, Colorado
Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Register for Updates